Asthma Drugs Market to Reach US$ 37.62 Billion by 2032 at 5.2% CAGR; North America Leads Biologic Adoption | Key Players AstraZeneca, GSK, Teva

The asthma drugs market reached US$ 25.72 billion in 2024 and is expected to reach US$ 37.62 billion by 2032, growing at a CAGR of 5.2% during the forecast period 2025-2032. Market growth is driven by the rising global prevalence of asthma, increasing exposure to air pollution and allergens, and growing awareness of disease management and early diagnosis. Advances in inhalation drug delivery systems, the introduction of long-acting combination therapies, and expanding use of biologic drugs for severe asthma are further supporting market expansion.

North America held the largest market share due to high diagnosis rates, strong access to advanced asthma therapies, favorable reimbursement policies, and the presence of leading pharmaceutical manufacturers. Europe followed with widespread adoption of guideline-based asthma management and strong public healthcare systems, while Asia-Pacific is expected to witness the fastest growth driven by a large patient population, rising urbanization, increasing air pollution levels, and improving access to respiratory care across emerging economies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/asthma-drugs-market?sai-v

The asthma drugs market refers to the global industry focused on medications used to prevent, control, and treat asthma and related respiratory conditions.

Key Developments
✅ January 2026: In North America, prescribing trends continued to shift toward biologic therapies targeting Type 2 inflammation (e.g., anti-IL-5, anti-IL-4/13 agents), driven by updated treatment guidelines emphasizing personalized approaches for severe asthma.

✅ January 2026: In Europe, healthcare systems expanded reimbursement and guideline recommendations for eosinophil-directed biologics, improving access and uptake among patients with severe and uncontrolled asthma.

✅ December 2025: In Asia-Pacific, pharmaceutical companies reported stronger demand for fixed-dose combination inhalers that simplify therapy regimens and improve adherence in moderate to severe asthma cases.

✅ December 2025: Globally, research investment increased in novel small-molecule bronchodilators and anti-inflammatory agents, including next-generation oral and inhaled therapies aimed at broader patient populations.

✅ November 2025: In Latin America, initiatives by payers and health authorities supported wider adoption of long-acting muscarinic antagonist (LAMA)-containing therapies as add-on options for patients not controlled on standard inhaled corticosteroid/long-acting beta-agonist regimens.

✅ October 2025: Worldwide, expanded clinical evidence reinforced the role of personalized treatment algorithms that integrate biomarkers and phenotyping to guide therapy selection and improve outcomes.

Mergers & Acquisitions
✅ January 2026: In the United States, a major pharmaceutical company acquired a biotech specializing in next-generation biologic therapies for severe asthma to strengthen its respiratory portfolio.

✅ December 2025: In Europe, a global pharma group completed the acquisition of an inhaled drug developer with advanced fixed-dose combination asthma therapies under late-stage clinical evaluation.

✅ November 2025: In Asia-Pacific, a regional drug manufacturer acquired rights to a novel small-molecule anti-inflammatory agent targeting asthma exacerbations to expand its respiratory franchise.

Key Players
AstraZeneca | GSK plc | Teva Pharmaceutical Industries Ltd. | Merck & Co., Inc. | Regeneron Pharmaceuticals, Inc. | Sanofi | Amgen Inc. | Covis Pharma | Camber Pharmaceuticals, Inc. | Others

Key Highlights
AstraZeneca holds 19.6% share, driven by strong performance in specialty and respiratory therapeutics, continuous pipeline expansion, and broad global regulatory approvals.

GSK plc holds 17.1% share, supported by its leadership in respiratory and immunology medicines, robust vaccine portfolio, and long-standing market presence.

Teva Pharmaceutical Industries Ltd. holds 14.3% share, leveraging its scale in generic and specialty medicines, cost-efficient manufacturing, and extensive global distribution network.

Merck & Co., Inc. holds 12.5% share, driven by innovative biologics and small-molecule therapies, strong R&D capabilities, and consistent product approvals.

Regeneron Pharmaceuticals, Inc. holds 10.8% share, supported by its expertise in monoclonal antibody development, high-efficacy biologics, and expanding specialty indications.

Sanofi holds 9.4% share, leveraging its strength in specialty care, immunology, and preventive therapeutics with a strong international footprint.

Amgen Inc. holds 8.2% share, driven by its biologics leadership, biosimilars portfolio, and continued innovation in chronic and specialty disease areas.

Covis Pharma holds 4.6% share, supported by its focus on specialty pharmaceuticals and respiratory treatments in targeted markets.

Camber Pharmaceuticals, Inc. holds 2.1% share, leveraging generic drug offerings and partnerships to serve cost-sensitive healthcare segments.

Others account for 1.4% share, comprising regional and niche pharmaceutical companies offering specialized and emerging therapeutic solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=asthma-drugs-market?sai-v

Market Drivers
- Rising global prevalence of asthma driven by increasing air pollution, urbanization, and lifestyle-related factors.

- Growing pediatric and geriatric asthma populations increasing long-term demand for maintenance and rescue therapies.

- Advancements in inhalation drug delivery systems improving treatment efficacy and patient adherence.

- Increasing adoption of biologic therapies for severe and uncontrolled asthma cases.

- Supportive reimbursement policies and updated clinical guidelines promoting early and sustained asthma management.

Industry Developments
- Expansion of biologic asthma drug portfolios targeting specific inflammatory pathways such as IL-5, IL-4/IL-13, and IgE.

- Development of next-generation inhalers with digital dose tracking and smart monitoring capabilities.

- Growing focus on combination therapies integrating corticosteroids and long-acting bronchodilators.

- Strategic collaborations and licensing agreements among pharmaceutical companies to strengthen respiratory drug pipelines.

- Increasing availability of generic and biosimilar asthma drugs improving treatment affordability and access.

Regional Insights
North America - 39% share: "Driven by high asthma prevalence, strong adoption of biologics, advanced healthcare infrastructure, and favorable reimbursement policies."

Europe - 28% share: "Supported by strong respiratory care guidelines, widespread use of combination inhalers, and growing biologic uptake."

Asia Pacific - 23% share: "Fueled by rising pollution levels, increasing asthma diagnosis rates, expanding healthcare access, and improving treatment awareness."

Latin America - 6% share: "Driven by improving access to respiratory treatments and growing focus on chronic disease management."

Middle East & Africa - 4% share: "Supported by increasing healthcare investments, rising awareness of respiratory disorders, and gradual adoption of advanced asthma therapies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/asthma-drugs-market?sai-v

Key Segments

By Drug Class
Inhaled corticosteroids dominate the market, driven by their role as first-line therapy for long-term asthma control and inflammation reduction. Leukotriene modifiers hold a significant share, supported by their oral administration and effectiveness in managing mild to moderate asthma and allergy-associated symptoms. Long-acting beta agonists (LABAs) account for a substantial segment, primarily used in combination with corticosteroids to improve symptom control and reduce exacerbations. Quick-relief medications represent a key segment, driven by their widespread use for acute symptom relief and emergency management. Combination inhalers are witnessing strong growth due to improved patient adherence and enhanced therapeutic efficacy through dual or triple drug formulations. Biologics constitute a rapidly expanding segment, supported by advancements in targeted therapies for severe and treatment-resistant asthma. Other drug classes include mast cell stabilizers and methylxanthines, contributing modestly to overall market growth.

By Route of Administration
Inhalation represents the dominant route of administration, supported by rapid drug delivery to the lungs, reduced systemic side effects, and high patient preference. Oral administration holds a notable share, driven by ease of use and availability of tablet-based therapies for long-term management. Other routes of administration, including injectable formulations for biologics, account for a smaller share and are primarily used in severe asthma cases under clinical supervision.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.